Pancreatic adenocarcinoma has a 13% 5-year survival rate and limited curative therapeutic options outside of surgical resection at an early stage. Recent studies have indicated that the few patients who live longer than 5 years with this disease have high-quality neoantigens: mutated cancer-specific proteins that are recognizable by the immune system. This has led to various approaches aimed at training the immune system to recognize these neoantigens in patients. Targeting neoantigens is a diff